NASDAQ:VNDA

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals shares jumped 33% to $7.68 in premarket trading Monday after the FDA approved its new antipsychotic pill, Bysanti, late Friday. The drug, milsaperidone, is bioequivalent to Vanda’s existing Fanapt and will be available commercially in the third quarter of 2026. Traders are watching whether the rally holds at the open and how Bysanti will compete in a crowded market.

23 February 2026

NASDAQ:VNDA·Pharmaceuticals·Stock Market

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Vanda Pharmaceuticals jumped 25% and Axsome rose 23% Wednesday after positive FDA decisions, while Corcept dropped 50% on a regulatory setback. The Health Care Select Sector SPDR Fund (XLV) slipped 0.6% as the S&P 500 fell 0.73%. U.S. markets were closed Thursday for New Year’s Day. Traders now await January macro data and managed-care earnings.

1 January 2026

NASDAQ:AXSM·NASDAQ:CORT·NASDAQ:VNDA

Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

The Nasdaq Composite dropped 0.8% Wednesday to close 2025 at 23,241.99, while the S&P 500 lost 0.7% and the Dow fell 0.6%. U.S. markets are closed Thursday for New Year’s Day. Investors await the Jan. 9 jobs report, Jan. 13 inflation data, and the start of bank earnings for direction. Trading volume was below average, with tech and energy shares leading declines.

1 January 2026

Nasdaq·NASDAQ:MSFT·NASDAQ:VNDA·NYSE:EQT·Stock Market

Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

Vanda Pharmaceuticals shares rose 28.1% to $9.01 after the FDA approved Nereus to prevent motion-induced vomiting. Late-stage trials showed vomiting rates of 10%–20% on Nereus versus 38%–44% on placebo. Vanda plans to launch the drug in the coming months, with investors watching pricing and rollout against established over-the-counter competitors.

31 December 2025

NASDAQ:VNDA·Pharmaceuticals

S&P 500 edges down in thin year-end trade as jobless claims fall; Nike, Vanda jump

The Dow fell 114.33 points to 48,252.73, the S&P 500 lost 16.62 to 6,879.62, and the Nasdaq slipped 51.05 to 23,368.03 in thin year-end trading. U.S. jobless claims dropped to 199,000, sending Treasury yields higher. Nike gained after CEO Elliott Hill bought shares. Vanda Pharmaceuticals surged on FDA approval for its motion sickness drug.

31 December 2025

NASDAQ:VNDA·NYSE:NKE·Stock Market

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharmaceuticals shares rose about 18% in premarket trading after the FDA approved its motion-sickness drug Nereus (tradipitant). The company plans to launch the oral treatment in the coming months. The approval followed late-stage trials involving 681 patients. Shares closed at $7.03 Tuesday and were indicated around $8.30 early Wednesday.

31 December 2025

Healthcare News·NASDAQ:VNDA·Pharmaceuticals·Stock Market

2 Canadian Dividend Stocks Ideal for Retirees in 2026
May 19, 2026, 12:58 PM EDT. National Bank of Canada (TSX:NA) and Restaurant Brands International (TSX:QSR) emerge as solid dividend stock choices for Canadian retirees amid a buoyant TSX Index. National Bank trades near all-time highs around CAD 204 with a 20x price-to-earnings (P/E) ratio and a 2.4% dividend yield, backed by growth prospects and strategic acquisitions like Canadian Western Bank. Restaurant Brands International, down 6% recently, offers a resilient 3.4% dividend yield and a 24.5 P/E multiple. Its brand strength in fast food and innovation spending support its value. Both stocks balance modest yields with growth potential, fitting retirees seeking income and stability in 2026's market environment.